ArticleScientific reports2025
A dispersion-corrected DFT calculation on the drug delivery of Bezafibrate using pectin biopolymer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the potential interaction of the antihyperlipidemic drug Bezafibrate with Pectin for drug delivery applications, using density functional theory (DFT) calculations. A detailed analysis of the geometrical, structural, electrical, and bonding properties was conducted. This included optimized geometry, adsorption energies, quantum molecular descriptors, topological parameters, and frontier molecular orbitals. The RDG iso-surface plot of the Bezafibrate@Pectin complex revealed that strong hydrogen bonding at two distinct sites with 1.56 Å and 1.73 Å bonds length, plays a critical role in the binding process. The calculated adsorption energy (-81.62 kJ/mol) between Bezafibrate and Pectin demonstrated a favorable binding affinity, suggesting the possibility of enhanced therapeutic efficacy. Further density of state (DOS) analysis indicated that upon adsorption, Bezafibrate undergoes significant electron minor hybridization, leading to marked changes in Pectin's electronic properties and heightened sensitivity to drug binding. The findings highlight that hydrogen bonds between the active sites of Bezafibrate and Pectin are pivotal in the adsorption mechanism of the complex. Additionally, the recovery time was estimated to analyze the interaction mechanism between the bezafibrate drug and pectin, as well as its effect on drug release. These insights contribute to the understanding of Pectin's polysaccharides in biomedical applications, particularly for advanced drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.